|
Nov 13
|
Novartis licenses Legend cell therapy for lung cancer
|
|
Nov 9
|
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
|
|
Nov 5
|
3 Spectacular High-Yield Dividend Stocks to Buy in November
|
|
Nov 3
|
Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues
|
|
Aug 31
|
Big Pharma's biggest ally gets trolled on X for attacking Medicare drug pricing list
|
|
Aug 30
|
Novartis (NVS) Stock Sinks As Market Gains: What You Should Know
|
|
Aug 30
|
Medicare price negotiation list: What it means for pharma companies
|
|
Aug 29
|
Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns
|
|
Aug 29
|
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca
|
|
Aug 29
|
AbbVie (ABBV) Seeks Approval for Skyrizi for Ulcerative Colitis
|
|
Aug 29
|
Novartis (NVS) Announces Positive Long-Term Data on Leqvio
|
|
Aug 28
|
Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar
|
|
Aug 28
|
Oncology Market's Huge Potential Puts These Stocks in Focus
|
|
Aug 28
|
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
|
|
Aug 28
|
Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio
|
|
Aug 25
|
Novartis comes for a Biogen MS drug with new biosimilar
|
|
Aug 25
|
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
|
|
Jul 21
|
Pharma Stock Roundup: JNJ, NVS Upbeat Q2 Results, FDA Nod to SNY & AZN RSV Antibody
|
|
Jul 20
|
UPDATE 2-Japan's Daiichi Sankyo gets US FDA nod for blood cancer treatment
|
|
Jul 20
|
Here's Why You Should Add Alnylam (ALNY) Stock to Your Portfolio
|